Nash Marc 4
4 · Outset Medical, Inc. · Filed Jan 22, 2025
Insider Transaction Report
Form 4
Nash Marc
EVP Operations R&D & Service
Transactions
- Award
Common Stock
2025-01-17+1,404→ 228,189 total - Sale
Common Stock
2025-01-21$0.80/sh−21,590$17,272→ 206,243 total - Award
Common Stock
2025-01-17+4,494→ 226,785 total - Sale
Common Stock
2025-01-21$0.80/sh−356$285→ 227,833 total - Sale
Common Stock
2025-01-21$0.80/sh−971$777→ 205,272 total - Sale
Common Stock
2025-01-21$0.80/sh−304$243→ 204,968 total
Footnotes (6)
- [F1]On March 15, 2023, the reporting person was granted performance-based restricted stock units (PSUs) subject to the satisfaction of specified performance criteria as of December 31, 2024. The reported amount represents the number of PSUs earned by the reporting person on January 17, 2025, upon certification by the Compensation Committee of the Issuer's Board of Directors of the satisfaction of specified performance criteria. Each PSU represents a contingent right to receive a share of common stock. These PSUs vested 50% on January 17, 2025, and the remaining 50% shall vest on December 31, 2025, subject to the reporting person's continuous service through the vesting period.
- [F2]On July 24, 2023, the reporting person was granted performance-based restricted stock units (PSUs) subject to the satisfaction of specified performance criteria as of December 31, 2024. The reported amount represents the number of PSUs earned by the reporting person on January 17, 2025, upon certification by the Compensation Committee of the Issuer's Board of Directors of the satisfaction of specified performance criteria. Each PSU represents a contingent right to receive a share of common stock. These PSUs vested 50% on January 17, 2025, and the remaining 50% shall vest on December 31, 2025, subject to the reporting person's continuous service through the vesting period.
- [F3]Required number of shares sold by the reporting person to cover tax withholding obligations in connection with 824 shares of Common Stock underlying PSUs which (i) were, as previously reported, granted to the reporting person on March 15, 2022, (ii) were earned as of January 26, 2024 as certified by the Compensation Committee of the Issuer's Board of Directors of the satisfaction of specified performance criteria, and (iii) vested and were released on January 17, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F4]Required number of shares sold by the reporting person to cover tax withholding obligations in connection with 50,000 shares of Common Stock underlying PRSUs which (i) represent 50% of the target shares underlying the original award (granted on January 12, 2024, as previously reported), which were earned based on performance as of December 31, 2024, upon certification by the Compensation Committee of the Issuer's Board of Directors, and (ii) vested and were released on January 17, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F5]Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 50% of the PSUs, described in footnote (1) above, on January 17, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F6]Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 50% of the PSUs, described in footnote (2) above, on January 17, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.